Diagnos Company Insiders
| ADK Stock | CAD 0.37 0.02 5.71% |
Diagnos employs about 5 people. The company is managed by 5 executives with a total tenure of roughly 34 years, averaging almost 6.0 years of service per executive, having 1.0 employees per reported executive. Recap of Diagnos' management performance can provide insight into the venture performance.
| Andre Larente CEO CEO and President and Executive Director |
| Guillermo Robles President Vice President - Health Care Business Development of Latin America |
Diagnos |
Diagnos Management Team Effectiveness
The company has return on total asset (ROA) of (1.3433) % which means that it has lost $1.3433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (24.5157) %, meaning that it generated substantial loss on money invested by shareholders. Diagnos' management efficiency ratios could be used to measure how well Diagnos manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 1.02 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (4.02). At this time, Diagnos' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 27.6 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 256.8 K in 2025.Common Stock Shares Outstanding is likely to climb to about 87.9 M in 2025, whereas Net Loss is likely to drop (2.5 M) in 2025.
Diagnos Workforce Comparison
Diagnos is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 0.0. Diagnos adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Diagnos Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Diagnos Price Series Summation is a cross summation of Diagnos price series and its benchmark/peer.
Diagnos Notable Stakeholders
A Diagnos stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Diagnos often face trade-offs trying to please all of them. Diagnos' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Diagnos' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andre Larente | CEO and President and Executive Director | Profile | |
| Guillermo Robles | Vice President - Health Care Business Development of Latin America | Profile | |
| MarcAndr Massue | CFO Finance | Profile | |
| Martin Beland | Director Marketing | Profile | |
| YvesStphane Couture | Chief Officer | Profile |
About Diagnos Management Performance
The success or failure of an entity such as Diagnos often depends on how effective the management is. Diagnos management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Diagnos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Diagnos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.23) | (4.02) | |
| Return On Capital Employed | 2.52 | 2.40 | |
| Return On Assets | (4.23) | (4.02) | |
| Return On Equity | 0.92 | 1.02 |
Please note, the imprecision that can be found in Diagnos' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Diagnos. Check Diagnos' Beneish M Score to see the likelihood of Diagnos' management manipulating its earnings.
Diagnos Workforce Analysis
Traditionally, organizations such as Diagnos use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Diagnos within its industry.Diagnos Manpower Efficiency
Return on Diagnos Manpower
| Revenue Per Employee | 34K | |
| Revenue Per Executive | 34K | |
| Net Loss Per Employee | 624.1K | |
| Net Loss Per Executive | 624.1K |
Additional Tools for Diagnos Stock Analysis
When running Diagnos' price analysis, check to measure Diagnos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diagnos is operating at the current time. Most of Diagnos' value examination focuses on studying past and present price action to predict the probability of Diagnos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diagnos' price. Additionally, you may evaluate how the addition of Diagnos to your portfolios can decrease your overall portfolio volatility.